“TIBBIYOT OLIYGOHLARIDA TABIIY FANLARNI
INTERFAOL USULLARDA O'QITISHNING
MUAMMOLARI VA YECHIMLARI”
173
3-SHOʻBA: TIBBIY-BIOLOGIK FANLARNI RAQAMLI VA INTERAKTIV
VOSITALARDA O‘QITISH MUAMMOLARI VA YECHIMLARI
ATHEROSCLEROSIS
Norqulova Y.R.
Student of the 401-A group, 2nd Faculty of Treatment, Tashkent State Medical University
(TSMU)
Email:
Scientific Advisor:
Tagayeva M.X
., Associate Professor, PhD in Medical Sciences
Abstract:
This thesis presents a comprehensive analysis of modern approaches to
atherosclerosis, including its etiopathogenesis, diagnostic capabilities, and preventive strategies based
on recent scientific studies. Disruptions in lipid metabolism, chronic inflammation, and endothelial
dysfunction are considered key pathogenic mechanisms. Recent discoveries regarding genetic factors,
microbiota involvement, and novel biomarkers have significantly expanded opportunities for early
diagnosis and treatment of atherosclerosis.
Keywords:
atherosclerosis, endothelial dysfunction, lipids, biomarkers, prevention
INTRODUCTION
Atherosclerosis is one of the leading etiological factors of cardiovascular diseases. According
to the World Health Organization (WHO, 2023), more than 17 million people die each year due to
cardiovascular complications, most of which are associated with atherosclerosis.
RECENT SCIENTIFIC ADVANCES
Recent studies (Libby et al., 2023) have demonstrated that atherosclerosis is not merely a
result of lipid accumulation, but also a chronic immune-inflammatory process, influenced by changes
in the gut microbiota. In particular, a metabolite called Trimethylamine-N-oxide (TMAO), produced
by intestinal flora, promotes plaque formation in blood vessels. Furthermore, genetic factors,
especially mutations in the PCSK9 gene, have become targets for new treatment strategies. The
development and clinical application of monoclonal antibodies (e.g., evolocumab, alirocumab) have
marked a breakthrough in lipid-lowering therapies.
DIAGNOSTICS AND BIOMARKERS
In addition to traditional lipid profiling, the following novel biomarkers are increasingly being
used in the diagnosis of atherosclerosis:
• hs-CRP (high-sensitivity C-reactive protein)
• Lipoprotein(a) – Lp(a)
• IL-6 and TNF-α – pro-inflammatory cytokines
Additionally, Coronary Artery Calcium (CAC) scoring is used to assess vascular calcification
and predict cardiovascular risk.
PREVENTION STRATEGIES
Modern atherosclerosis prevention includes a combination of pharmacological and lifestyle
interventions:
1. Statins and PCSK9 inhibitors to lower LDL cholesterol
2. Pre- and probiotics to optimize gut microbiota
3. Anti-inflammatory medications (e.g., colchicine)
4. Lifestyle modification: healthy diet, regular physical activity, smoking cessation
CONCLUSION
Atherosclerosis is a complex and multifactorial pathological condition. Recent advances
highlight the importance of addressing inflammation, genetic predisposition, and gut microbiota in
both prevention and treatment. Integrating new biomarkers and personalized therapy significantly
enhances early diagnosis and risk stratification.
“TIBBIYOT OLIYGOHLARIDA TABIIY FANLARNI
INTERFAOL USULLARDA O'QITISHNING
MUAMMOLARI VA YECHIMLARI”
174
REFERENCES
[1] Libby P., Hansson G.K. From Focal Lipid Storage to Systemic Inflammation: JACC State-
of-the-Art Review. J Am Coll Cardiol. 2023;81(6):635–652.
[2] Timmis A. et al. European Society of Cardiology Cardiovascular Disease Statistics 2023.
Eur Heart J. 2023;44(6):503–596.
[3] Ridker P.M. Inflammation, C-Reactive Protein, and Cardiovascular Risk: Past, Present,
and Future. Circ Res. 2023;132(1):1–18.
[4] Wang Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular
disease. Nature. 2023; 572:57–63.
[5] Sabatine M.S. et al. PCSK9 Inhibitors in Lipid Management: Real-World Effectiveness.
N Engl J Med. 2022; 386:1803–1813.
